What Can Be Done to Reduce the Risk of Colitis-Associated Cancer in UC Patients?
the MPR take:
While ulcerative colitis (UC) patients have an increased risk of developing dysplasia and colitis-associated cancer (CAC), the use of anti-inflammatory medications may reduce the need to undergo colectomy and the risk of CAC. A study of 434 patients with a confirmed diagnosis of UC that were treated from 2002–2013 were evaluated for length of disease duration, need for colectomy, and CAC diagnosis. CAC risk was strongly associated with length of disease duration, with a disease duration of >15 years linked to the greatest risk of colectomy vs. those in the first eight years of the disease. Therapy with anti-inflammatory or immunosuppressive medications (eg, 5-ASA, anti-TNF blockers) had significantly reduced the risk of both dysplasia and CAC; patients taking 5-ASA had a markedly lower risk of colectomy vs. those on no medications (OR 0.2; 95 % CI 0.1–0.4; P<0.001). Given that anti-inflammatory treatment, especially 5-ASA, can reduce the risk of dysplasia, colectomy, and CRC, clinicians should promote early and consistent therapies in UC patients. Other factors such as chemopreventive drugs and appropriate endoscopic surveillance need to be further evaluated, add the researchers.
Ulcerative colitis increases the risk of developing dysplasia and colitis-associated cancer (CAC). The purpose of this study was to determine the risk factors as well as protective measures for disease burden, need for colectomy and the development of CAC in ulcerative colitis (UC) patients.